NCT07786389Enrolling by invitationPhase 1/2
Seaweed Extract (Fucoidan) for Gut Inflammation in Ulcerative Colitis
Effects of Brown Algae (Turbinaria Ornata) Derived Fucoidan on Intestinal Inflammation and Gut Health in Ulcerative Colitis Patients
Source: ClinicalTrials.gov · Last updated 26 Aug 2026
Brief summary (registry, in English)
What is the research question being addressed? Does combining Turbinaria ornata-derived fucoidan with standard therapy lead to a significantly higher rate of gut health restoration-defined by increased fecal short-chain fatty acid (butyrate/acetate) levels, reduced fecal calprotectin, and improved stool consistency-compared to standard therapy alone in Ulcerative Colitis patients? Type of study: Interventional Study design: Randomized controlled trial Masking: Participants Control: Placebo Assignment: Parallel Purpose: Other Adjuvant / Add-On Therapy (Complementary Prebiotic Strategy) Study Phase: Phase1
- Status (registry)
- Enrolling by invitation
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 15 Aug 2026
- Start date
- 1 Aug 2026
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- Allama Iqbal Medical College
- Diseases
- Ulcerative colitis
- NCT number
- NCT07786389
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 90
- From 1 Aug 2026 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Male and female patients aged between 18-64 years;
- Active mild to moderate diagnosed cases of uc
- Voluntarily agreeing to participate and providing informed consent.
- Exclusion Criteria:
- Other autoimmune disorders and chronic diseases.
- Patient with Clotting problems.
- Patients using oral/intravenous steroids, leukotriene antagonists, immunosuppressant's, systemic photo chemotherapy, immunotherapy, allergen-specific immunotherapy, or Chinese herbal medicine within one month before enrolment.
- Patient unable to take the trial supplements as scheduled or cooperate in filling out the questionnaire and taking a blood test.
- Patients with a history of allergy
- Patients suffering from serious infection requiring hospitalization assessed by a clinician
- Severe organ dysfunction (e.g., heart failure, liver failure, liver cirrhosis, or renal failure assessed by a clinician.
- Pregnant women or those preparing for pregnancy, and those in lactation.
- Patient with hypothyroidism.
- Patients with a history of allergy to Soy.
- Acute severe (fulminant) UC
Age in the registry: 18 years to 64 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Allama Iqbal Medical college Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.